Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive�compulsive disorder: A placebo-controlled, double-blind, randomized trial

Esalatmanesh, S. and Abrishami, Z. and Zeinoddini, A. and Rahiminejad, F. and Sadeghi, M. and Najarzadegan, M.-R. and Shalbafan, M.-R. and Akhondzadeh, S. (2016) Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive�compulsive disorder: A placebo-controlled, double-blind, randomized trial. Psychiatry and Clinical Neurosciences, 70 (11). pp. 517-526.

[img] Text
Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive–compulsive disorder A placebo-controlled, double-blind, randomized trial.pdf

Download (705kB)
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Aim: Several lines of evidence implicate glutamatergic dysfunction in the pathophysiology of obsessive�compulsive disorder (OCD), presenting this neurotransmitter as a target for the development of novel pharmacotherapy. The objective of this study was to assess the efficacy of minocycline as an augmentative agent to fluvoxamine in the treatment of patients with OCD. Methods: One hundred and two patients with the diagnosis of moderate-to-severe OCD were recruited to this study. A randomized double-blind trial was designed and patients received either L-carnosine or placebo as adjuvant to fluvoxamine for 10 weeks. The patients randomly received either minocycline 100 mg twice per day or placebo for 10 weeks. All patients received fluvoxamine (100 mg/day) for the first 4 weeks, followed by 200 mg/day for the rest of the trial, regardless of their treatment groups. Participants were evaluated using the Yale�Brown Obsessive Compulsive Scale (Y-BOCS). The main outcome measure was to assess the efficacy of minocycline in improving the OCD symptoms. Results: General linear model repeated measures demonstrated significant effect for time � treatment interaction on the Y-BOCS total scores, F(1.49, 137.93) = 7.1, P = 0.003, and Y-BOCS Obsession subscale score, F(1.54, 141.94) = 9.72, P = 0.001, and near significant effect for the Y-BOCS Compulsion subscale score, F(1.27, 117.47) = 2.92, P = 0.08. A significantly greater rate of partial and complete response was observed in the minocycline group (P < 0.001). The frequency of side-effects was not significantly different between the treatment arms. Conclusion: The results of this study suggest that minocycline could be a tolerable and effective adjuvant in the management of patients with OCD. © 2016 The Authors. Psychiatry and Clinical Neurosciences © 2016 Japanese Society of Psychiatry and Neurology

Item Type: Article
Additional Information: cited By 5
Subjects: WM Psychiatry
QV Pharmacology
Depositing User: eprints admin
Date Deposited: 08 Jul 2018 03:53
Last Modified: 08 Oct 2019 09:49
URI: http://eprints.iums.ac.ir/id/eprint/3074

Actions (login required)

View Item View Item